Skip to main content
Premium Trial:

Request an Annual Quote

PositiveID Board Approves 1-for-25 Reverse Stock Split

NEW YORK (GenomeWeb News) – PositiveID said today its board has approved a 1-for-25 reverse stock split, commencing at the start of trading on April 23.

As a result of the reverse split, the number of PositiveID shares will be reduced to about 15 million shares. The company's ticker symbol will be PSIDD for about 20 trading days after the split to designate it is trading on a post-reverse split basis.

The company trades on the Over-The-Counter Bulletin Board.

PositiveID has focused on its molecular diagnostic technologies for biothreat detection and rapid medical testing during the past two years, and the Delray Beach, Fla.-based firm said that the reverse split "could enhance the appeal of its common stock to the financial community," including institutional investors, potential new strategic partners, and the general investing public

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.